Overview

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib